From: Prognostic value of ERBB4 expression in patients with triple negative breast cancer
Clinical variables | HR | 95% CI | p-value |
---|---|---|---|
(A) All stages | Â | Â | Â |
Stage | Â | Â | <0.001 |
 I | 1.0 | NA |  |
 IIA | 1.37 | 0.47 – 4.01 |  |
 IIB | 3.28 | 1.07 – 10.04 |  |
 IIIA | 4.81 | 1.39 – 16.65 |  |
 IIIC | 35.12 | 9.62 – 128.27 |  |
ERBB4 (median: 1.3) | Â | Â | 0.005 |
 Low | 1.0 | NA |  |
 High | 3.12 | 1.42 – 6.87 |  |
(B) Early stage (N = 149) |  |  |  |
Stage | Â | Â | 0.669 |
 I | 1.0 | NA |  |
 IIA | 1.37 | 0.43 – 3.77 |  |
ERBB4 (median: 1.3) | Â | Â | 0.728 |
 Low | 1.0 | NA |  |
 High | 1.21 | 0.41 – 3.55 |  |
(C) Advanced stage (N = 54) |  |  |  |
Stage | Â | Â | <0.001 |
 IIB | 1.0 | NA |  |
 IIIA | 1.12 | 0.33 – 3.83 |  |
 IIIC | 35.71 | 6.73 – 189.65 |  |
ERBB4 (median: 1.3) | Â | Â | 0.004 |
 Low | 1.0 | NA |  |
 High | 7.79 | 1.96 – 31.01 |  |